|
|
|
| Surveillance results of adverse events following immunization with meningococcus-containing vaccine in Jiaxing City |
| DU Zhequn1, TANG Xian1, YU Pengfei1, GAN Zhengkai2, SONG Yiping1, HU Jie1
|
1. Jiaxing Center for Disease Control and Prevention, Jiaxing, Zhejiang 314050, China;
2. Xiuzhou District Center for Disease Control and Prevention, Jiaxing, Zhejiang 314031, China |
|
|
|
|
Abstract Objective To investigate the occurrence of adverse events following immunization (AEFI) with meningococcus-containing vaccine (MCV) in Jiaxing City, Zhejiang Province from 2020 to 2024, so as to provide the evidence for MCV safety monitoring and evaluation. Methods AEFI surveillance data following MCV vaccination were collected through the Immunization Program Information Management System of the China Disease Prevention and Control Information System, and MCV vaccination data were collected through the Zhejiang Provincial Immunization Program Smart Service Information System. Descriptive analyses were performed to examine the demographic distribution, temporal distribution, and regional distribution of AEFI cases, as well as the doses of MCV administered, the interval between vaccination and AEFI onset, clinical symptoms of AEFI, and outcomes. Results From 2020 to 2024, a total of 263 AEFI cases were reported in Jiaxing City, with an average annual reported incidence of 27.73/105 doses, showing an increasing trend (P<0.05). Common adverse reactions predominated, accounting for 230 cases (87.45%), with the reported incidence of 24.25/105 doses. Among AEFI cases, 139 (52.85%) were males and 124 (47.15%) were females. The majority of cases were aged <2 years, accounting for 156 cases (59.32%). The number of reported AEFI cases was relatively high in the second and third quarters, with 75 and 77 cases, accounting for 28.52% and 29.28%, respectively, and reported incidence of 29.48/105 doses and 29.71/105 doses, respectively. Haiyan County and Pinghu City reported relatively higher numbers of cases, with 44 cases each, accounting for 16.73% each, and reported relatively higher AEFI incidence of 58.91/105 doses and 40.46/105 doses, respectively. Following the 1st, 2nd, 3rd, and 4th doses of MCV, 136, 111, 14, and 2 AEFI cases were reported, accounting for 51.71%, 42.21%, 5.32%, and 0.76%, respectively, with reported incidence of 30.63/105 doses, 23.24/105 doses, 55.59/105 doses, and 120.63/105 doses, respectively. A total of 198 AEFI cases (75.29%) were reported within 1 day after MCV vaccination. Among common adverse reaction cases, the predominant clinical symptoms were fever and local redness/swelling, occurring in 151 and 49 cases, accounting for 57.41% and 18.63%, respectively, with reported incidence of 15.92/105 doses and 5.17/105 doses, respectively. Conclusions From 2020 to 2024, the average annual reported incidence of AEFI following vaccination with five types of MCV in Jiaxing City was relatively low, but an increasing trend was observed. Common adverse reactions predominated. AEFI cases were concentrated in children aged <2 years, with relatively higher incidence in summer and autumn, as well as in Haiyan County and Pinghu City. Most cases occurred after the first dose of MCV and within 1 day post-vaccination, with fever and local redness/swelling being the main clinical symptoms.
|
|
Received: 07 January 2026
Revised: 26 March 2026
Published: 21 April 2026
|
|
|
|
|
|
[1] 徐娟,严冬山,徐丽,等.全球脑膜炎球菌多糖结合疫苗研究进展[J].中华微生物学和免疫学杂志,2024,44(4):304-316.
[2] 邓璇,周洋,严睿,等.ACWY四价脑膜炎球菌多糖结合疫苗的免疫策略及血清学免疫持久性研究进展[J].中华医学杂志,2023,103(44):3597-3602.
[3] 中华预防医学会.中国脑膜炎球菌疫苗预防接种专家共识(2023年版)[J].中国疫苗和免疫,2023,29(1):90-101.
[4] 蒋征刚,李倩,唐学雯.浙江省1997—2006年流行性脑脊髓膜炎流行情况分析[J].浙江预防医学,2008,20(12):19-20.
[5] 邓璇,姚苹苹,何寒青,等.2006—2017年浙江省流行性脑脊髓膜炎流行病学特征及菌群变迁趋势分析[J].疾病监测,2018,33(7):547-551.
[6] 吴琳琳,刘捷宸,邵慧勇,等.上海市2015—2018年含脑膜炎球菌成分疫苗疑似预防接种异常反应监测分析[J].中国生物制品学杂志,2020,33(7):813-817.
[7] 张丽娜,李媛,李克莉,等.2021—2022年中国疑似预防接种异常反应监测[J].中国疫苗和免疫,2024,30(4):470-484.
[8] 张丽娜,李克莉,李燕,等.2023年中国疑似预防接种异常反应监测[J].中国疫苗和免疫,2025,31(2):121-131.
[9] 薛茜茜,师建起,王庭柱.2020—2024年河南省南阳市疑似预防接种异常反应监测分析[J].现代疾病预防控制,2026,37(2):126-130,136.
[10] 武文娣,刘大卫,李克莉,等.2010—2012年中国脑膜炎球菌疫苗预防接种不良反应监测分析[J].中国药物评价,2014,31(2):117-121,128.
[11] 黄文俊,韦性晶,鲁梦婷,等.2016—2021年新疆生产建设兵团含脑膜炎球菌成分疫苗疑似预防接种异常反应监测分析[J].疾病预防控制通报,2023,38(5):1-4.
[12] 朱家佳,苏柳芊,田庆庆,等.2019—2023年贵阳市云岩区疑似预防接种异常反应监测情况分析[J].实用预防医学,2025,32(8):965-969.
[13] 朱迪,骆晓艳,李永成,等.2023—2024年天津市疑似预防接种异常反应监测分析[J].职业与健康,2025,41(24):3419-3422.
[14] 杜哲群,胡洁,沈国初,等.嘉兴市8月龄儿童接种MMR、MR疫苗疑似预防接种异常反应监测结果[J].预防医学,2020,32(11):1086-1090.
[15] 高洪敏,常利民.预防接种与过敏性休克的研究进展[J].中国生物制品学杂志,2017,30(5):557-560.
[16] 许玉洋,李克莉,李燕,等.中国2010—2022年乙型肝炎疫苗疑似预防接种异常反应监测分析[J].中国疫苗和免疫,2024,30(5):544-549.
[17] 谢志强,黄海涛,张伟,等.一种国产ACYW135群脑膜炎球菌多糖结合疫苗在3月龄、6~23月龄和2~6岁儿童中安全性的Ⅲ期临床试验[J].中国疫苗和免疫,2021,27(6):648-654.
[18] 赵东阳,万鹏,由汪洋,等.国产ACYW135群脑膜炎球菌多糖结合疫苗儿童12月龄加强免疫安全性和免疫原性的Ⅲ期临床试验[J].中国疫苗和免疫,2022,28(6):666-672. |
|
|
|
